The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer

PURPOSE: Anlotinib is an anti-angiogenetic multi-targeted tyrosine kinase inhibitor. This study aimed to evaluate the efficacy and safety of anlotinib in advanced non-small cell lung cancer (aNSCLC) in the real world. METHODS: Patients with aNSCLC receiving anlotinib were enrolled in two cohorts (tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Fen, Jin, Feng, Cheng, Boran, Zhang, Yue, Zhou, Qing, Wang, Shubin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article – Clinical Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343360/
https://www.ncbi.nlm.nih.gov/pubmed/34357411
http://dx.doi.org/10.1007/s00432-021-03752-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343360/
https://www.ncbi.nlm.nih.gov/pubmed/34357411
http://dx.doi.org/10.1007/s00432-021-03752-x

Ejemplares similares